The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC).
 
Jian-Ming Xu
No Relationships to Disclose
 
Ken Kato
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Richard Hubner
Honoraria - Abbott Nutrition; Ipsen
Consulting or Advisory Role - BTG; Shire
Travel, Accommodations, Expenses - Bayer; Celgene
 
Eric Raymond
No Relationships to Disclose
 
Yihuan Xu
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Sumei Liu
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Ibrahim Qazi
Employment - Five Prime Therapeutics
Stock and Other Ownership Interests - Exelixis; Five Prime Therapeutics
Travel, Accommodations, Expenses - Five Prime Therapeutics
 
Harry H. Yoon
Honoraria - Astellas Scientific and Medical Affairs Inc; LSK Biopharma; Merck Sharp & Dohme
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; LSK Biopharma; Merck
Research Funding - Boston Biomedical (Inst); Lilly/ImClone (Inst); Merck (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Lilly